By Stuart Condie
SYDNEY–Immutep shares are on course for their best day since June after the Australia-listed developer of cancer treatments presented clinical data from a Phase II trial of its lead product candidate in non-small cell lung cancer.
Immutep on Monday presented trial results in which patients treated with Immutep’s Efti in combination with Merck & Co.’s Keytruda pembrolizumab drug showed a median 12 months survival benefit compared with those treated with chemotherapy and Keytruda.
“The strength of the data positions us well as we continue to plan and prepare for our Phase III trial that we expect to launch next year,” Immutep Chief Executive Marc Voigt said in a market filing.
Shares in Immutep were up 13% at 31 Australian cents (19.6 U.S. cents).
Efti stimulates both innate and adaptive immunity for the treatment of cancer, Immutep said. It is under evaluation for a variety of solid tumors, including metastatic breast cancer.
Write to Stuart Condie at [email protected]
Read the full article here
